Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Biolase (BIOL – Research Report) yesterday and set a price target of $2.00. The company's shares closed last Tuesday at $0.41, close to its 52-week low of $0.27. According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 8.1% and a 38.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as ReShape Lifesciences, Milestone Scientific, and Dermata Therapeutics. Biolase has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, a 412.8% upside from current levels.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-biolases-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Biolase Charts.
Biolase (NASDAQ:BIOL)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Biolase Charts.